micafungin ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antifungal antibiotics 1798 235114-32-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • mycamine
  • micafungin
  • micafungin sodium
  • FK-463
  • FK463
A cyclic lipo-hexapeptide echinocandin antifungal agent that is used for the treatment and prevention of CANDIDIASIS.
  • Molecular weight: 1270.28
  • Formula: C56H71N9O23S
  • CLOGP: -1.99
  • LIPINSKI: 3
  • HAC: 32
  • HDO: 16
  • TPSA: 510.14
  • ALOGS: -3.77
  • ROTB: 18

Drug dosage:

DoseUnitRoute
0.10 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 1 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 6.30 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 0.21 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 0.17 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.00 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 16 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
March 16, 2005 FDA FUJISAWA HLTHCARE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 201.23 25.45 135 6273 97532 50501184
Pre-engraftment immune reaction 170.31 25.45 29 6379 209 50598507
Human herpesvirus 6 infection 157.17 25.45 41 6367 2565 50596151
Encephalitis viral 145.68 25.45 35 6373 1562 50597154
Multiple organ dysfunction syndrome 114.17 25.45 74 6334 50263 50548453
Cytomegalovirus test positive 105.86 25.45 30 6378 2562 50596154
Acute graft versus host disease 93.33 25.45 30 6378 3928 50594788
Sepsis 84.98 25.45 94 6314 132831 50465885
Acute graft versus host disease in skin 84.15 25.45 26 6382 2992 50595724
Bacterial sepsis 79.56 25.45 26 6382 3586 50595130
Pneumonia fungal 78.88 25.45 27 6381 4293 50594423
Aplastic anaemia 77.27 25.45 31 6377 7672 50591044
Hepatic function abnormal 69.06 25.45 46 6362 32635 50566081
Aspergillus infection 66.86 25.45 27 6381 6794 50591922
Thrombotic microangiopathy 66.72 25.45 29 6379 8762 50589954
Cytomegalovirus viraemia 65.32 25.45 24 6384 4685 50594031
Mucormycosis 63.40 25.45 20 6388 2463 50596253
Engraft failure 60.91 25.45 13 6395 337 50598379
Septic shock 59.91 25.45 53 6355 57122 50541594
Gastrointestinal fungal infection 58.46 25.45 12 6396 256 50598460
Cytomegalovirus infection 57.62 25.45 33 6375 17929 50580787
Meningoencephalitis herpetic 55.73 25.45 15 6393 1057 50597659
Pyrexia 55.04 25.45 137 6271 380066 50218650
Bronchopulmonary aspergillosis 54.22 25.45 24 6384 7568 50591148
Off label use 53.67 25.45 156 6252 474270 50124446
Graft versus host disease 52.26 25.45 22 6386 6144 50592572
Sinus polyp 50.76 25.45 11 6397 307 50598409
Pathogen resistance 50.58 25.45 21 6387 5668 50593048
Product use in unapproved indication 49.67 25.45 67 6341 115752 50482964
Enterococcal sepsis 48.65 25.45 14 6394 1261 50597455
Respiratory failure 47.33 25.45 58 6350 91123 50507593
Weissella infection 47.20 25.45 7 6401 17 50598699
Liver abscess 46.53 25.45 16 6392 2577 50596139
Systemic mycosis 46.16 25.45 13 6395 1084 50597632
Platelet count decreased 42.76 25.45 58 6350 100668 50498048
Aspartate aminotransferase increased 42.73 25.45 51 6357 77947 50520769
Plasma cell leukaemia 42.58 25.45 12 6396 1003 50597713
Hypoalbuminaemia 42.40 25.45 22 6386 9838 50588878
Haemophagocytic lymphohistiocytosis 42.19 25.45 21 6387 8612 50590104
Systemic candida 41.60 25.45 15 6393 2775 50595941
Fatigue 41.53 25.45 19 6389 707582 49891134
Disseminated intravascular coagulation 40.79 25.45 26 6382 17109 50581607
Nasal abscess 40.53 25.45 8 6400 139 50598577
Biloma 40.02 25.45 7 6401 60 50598656
Enterobacter infection 39.20 25.45 13 6395 1875 50596841
Acute myeloid leukaemia recurrent 38.85 25.45 12 6396 1378 50597338
Fungaemia 38.39 25.45 13 6395 1999 50596717
Encephalitis fungal 37.62 25.45 6 6402 27 50598689
Arthralgia 36.39 25.45 6 6402 438696 50160020
Mucosal erosion 35.51 25.45 11 6397 1276 50597440
Alanine aminotransferase increased 34.67 25.45 49 6359 88310 50510406
Chronic graft versus host disease 33.89 25.45 13 6395 2854 50595862
Fungal infection 33.82 25.45 29 6379 29936 50568780
Cytokine release syndrome 33.54 25.45 18 6390 8616 50590100
Epstein-Barr virus associated lymphoproliferative disorder 32.57 25.45 11 6397 1678 50597038
Enterococcal infection 31.42 25.45 16 6392 6882 50591834
Trichosporon infection 30.83 25.45 7 6401 243 50598473
Liver disorder 30.29 25.45 30 6378 37192 50561524
Pain 30.27 25.45 18 6390 578885 50019831
Cryptosporidiosis infection 29.79 25.45 7 6401 283 50598433
Renal impairment 29.74 25.45 42 6366 75619 50523097
Acute respiratory distress syndrome 29.22 25.45 23 6385 21076 50577640
Drug ineffective for unapproved indication 29.04 25.45 23 6385 21258 50577458
Acute graft versus host disease in intestine 28.97 25.45 10 6398 1629 50597087
Aspergillus test positive 28.87 25.45 7 6401 324 50598392
Pleural effusion 28.79 25.45 43 6365 81411 50517305
Varicella zoster virus infection 28.40 25.45 11 6397 2478 50596238
Oral fungal infection 28.38 25.45 11 6397 2484 50596232
Mixed liver injury 28.20 25.45 12 6396 3439 50595277
White blood cell count decreased 27.05 25.45 51 6357 116671 50482045
Fall 26.83 25.45 5 6403 334927 50263789
Blood bilirubin increased 26.39 25.45 26 6382 32012 50566704
Dizziness 26.04 25.45 6 6402 346363 50252353
Post transplant lymphoproliferative disorder 25.93 25.45 12 6396 4192 50594524
Differentiation syndrome 25.85 25.45 8 6400 925 50597791

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 174.50 19.82 206 10237 112034 29452050
Acute graft versus host disease in skin 153.95 19.82 59 10384 4605 29559479
Aplastic anaemia 145.78 19.82 65 10378 7445 29556639
Multiple organ dysfunction syndrome 132.89 19.82 136 10307 62980 29501104
Bronchopulmonary aspergillosis 104.47 19.82 61 10382 12283 29551801
Aspergillus infection 102.20 19.82 57 10386 10524 29553560
Herpes simplex oesophagitis 100.27 19.82 20 10423 119 29563965
Disseminated intravascular coagulation 95.58 19.82 69 10374 19911 29544173
Graft versus host disease 93.35 19.82 52 10391 9576 29554508
Acute graft versus host disease in intestine 89.54 19.82 33 10410 2308 29561776
Cytomegalovirus viraemia 89.50 19.82 44 10399 6276 29557808
Acute graft versus host disease 86.83 19.82 42 10401 5782 29558302
Candida infection 80.73 19.82 56 10387 15169 29548915
Cystitis haemorrhagic 66.44 19.82 33 10410 4809 29559275
Trichosporon infection 65.45 19.82 19 10424 621 29563463
Respiratory failure 64.94 19.82 120 10323 97011 29467073
Mucormycosis 64.47 19.82 33 10410 5125 29558959
Cytomegalovirus test positive 64.40 19.82 29 10414 3394 29560690
Product use in unapproved indication 64.04 19.82 112 10331 86763 29477321
Fungal infection 62.57 19.82 46 10397 13639 29550445
Fungaemia 59.34 19.82 24 10419 2157 29561927
Pyrexia 57.08 19.82 226 10217 287396 29276688
Venoocclusive liver disease 55.40 19.82 33 10410 6884 29557200
Acute graft versus host disease in liver 55.40 19.82 20 10423 1318 29562766
Fatigue 54.48 19.82 22 10421 316799 29247285
Fusarium infection 53.19 19.82 18 10425 979 29563105
Pre-engraftment immune reaction 52.31 19.82 11 10432 88 29563996
Sepsis 50.79 19.82 137 10306 142545 29421539
Cytomegalovirus infection 48.69 19.82 50 10393 23165 29540919
Septic shock 46.50 19.82 81 10362 62479 29501605
Glomerulosclerosis 46.43 19.82 15 10428 705 29563379
Acute myeloid leukaemia recurrent 46.41 19.82 19 10424 1761 29562323
Human herpesvirus 6 infection 45.58 19.82 19 10424 1844 29562240
Chronic graft versus host disease 45.26 19.82 24 10419 4005 29560079
Staphylococcal sepsis 43.26 19.82 31 10412 8831 29555253
Enterococcal infection 42.85 19.82 30 10413 8238 29555846
Cytokine release syndrome 42.50 19.82 36 10407 13083 29551001
Systemic candida 41.28 19.82 20 10423 2760 29561324
Botulism 41.22 19.82 10 10433 160 29563924
Hepatic function abnormal 40.41 19.82 59 10384 39200 29524884
Dizziness 40.08 19.82 9 10434 189675 29374409
Encephalitis viral 39.79 19.82 15 10428 1117 29562967
Haemophagocytic lymphohistiocytosis 36.46 19.82 30 10413 10474 29553610
Systemic mycosis 34.10 19.82 14 10429 1307 29562777
Cholestatic liver injury 33.91 19.82 15 10428 1682 29562402
Rhinocerebral mucormycosis 32.68 19.82 9 10434 242 29563842
Graft versus host disease in gastrointestinal tract 32.67 19.82 18 10425 3240 29560844
Off label use 32.57 19.82 199 10244 300601 29263483
Pneumonia fungal 32.38 19.82 22 10421 5755 29558329
Geotrichum infection 31.69 19.82 10 10433 435 29563649
Kidney fibrosis 31.22 19.82 15 10428 2032 29562052
Immunosuppressant drug level increased 31.21 19.82 20 10423 4745 29559339
Fall 30.87 19.82 12 10431 177166 29386918
Cystitis viral 30.24 19.82 10 10433 506 29563578
Necrotising oesophagitis 30.13 19.82 10 10433 512 29563572
Drug ineffective 29.62 19.82 224 10219 362946 29201138
Graft versus host disease in skin 29.37 19.82 17 10426 3362 29560722
Candida sepsis 29.32 19.82 12 10431 1111 29562973
Drug resistance 29.18 19.82 37 10406 21503 29542581
Renal failure 29.08 19.82 100 10343 118499 29445585
Delayed graft function 29.03 19.82 14 10429 1913 29562171
Mucosal disorder 28.98 19.82 13 10430 1507 29562577
Bacteraemia 28.65 19.82 32 10411 16291 29547793
Myocardial infarction 28.32 19.82 3 10440 110293 29453791
Idiopathic pneumonia syndrome 28.27 19.82 8 10435 238 29563846
Platelet count decreased 28.09 19.82 91 10352 104581 29459503
Pseudomembranous colitis 27.85 19.82 15 10428 2582 29561502
Cerebral aspergillosis 27.14 19.82 12 10431 1344 29562740
Reactive gastropathy 26.71 19.82 7 10436 155 29563929
Thymus hypoplasia 26.50 19.82 7 10436 160 29563924
Lymphoid tissue hypoplasia 26.50 19.82 7 10436 160 29563924
Mucosal inflammation 26.22 19.82 43 10400 31552 29532532
Enterococcal sepsis 25.97 19.82 12 10431 1490 29562594
Functional gastrointestinal disorder 25.04 19.82 13 10430 2077 29562007
Liver disorder 24.71 19.82 39 10404 27710 29536374
Infection 24.57 19.82 71 10372 76680 29487404
Thrombotic microangiopathy 24.44 19.82 22 10421 8659 29555425
Engraft failure 24.11 19.82 8 10435 409 29563675
Product dose omission issue 23.79 19.82 3 10440 96380 29467704
Ophthalmic vein thrombosis 23.56 19.82 5 10438 42 29564042
Klebsiella infection 23.45 19.82 20 10423 7329 29556755
Bacterial toxaemia 22.32 19.82 6 10437 147 29563937
Tumour lysis syndrome 22.30 19.82 26 10417 13858 29550226
Antithrombin III decreased 22.22 19.82 7 10436 303 29563781
Weight decreased 22.02 19.82 13 10430 150892 29413192
Engraftment syndrome 21.98 19.82 9 10434 834 29563250
Alternaria infection 21.85 19.82 7 10436 320 29563764
Neurological symptom 21.71 19.82 14 10429 3356 29560728
Cerebral ventricle collapse 21.37 19.82 5 10438 68 29564016
Skin necrosis 21.01 19.82 16 10427 4996 29559088
Somnolence 20.76 19.82 4 10439 93951 29470133
Staphylococcal infection 20.58 19.82 37 10406 29203 29534881
Adenoviral haemorrhagic cystitis 20.42 19.82 7 10436 396 29563688
Blood bilirubin increased 20.27 19.82 40 10403 33853 29530231
Device related sepsis 20.23 19.82 12 10431 2483 29561601
Depression 20.19 19.82 3 10440 85144 29478940
Disseminated aspergillosis 20.12 19.82 7 10436 414 29563670
Drug-induced liver injury 20.06 19.82 31 10412 21624 29542460
Venoocclusive disease 20.03 19.82 12 10431 2527 29561557

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 326.74 20.43 308 15449 187349 64295626
Aplastic anaemia 218.36 20.43 93 15664 13827 64469148
Pre-engraftment immune reaction 207.10 20.43 40 15717 301 64482674
Multiple organ dysfunction syndrome 206.50 20.43 182 15575 101231 64381744
Human herpesvirus 6 infection 175.24 20.43 59 15698 4595 64478380
Encephalitis viral 168.93 20.43 49 15708 2331 64480644
Aspergillus infection 163.82 20.43 80 15677 16299 64466676
Acute graft versus host disease 146.79 20.43 62 15695 9022 64473953
Cytomegalovirus viraemia 145.87 20.43 65 15692 10763 64472212
Acute graft versus host disease in skin 131.86 20.43 53 15704 6802 64476173
Bronchopulmonary aspergillosis 129.88 20.43 72 15685 19013 64463962
Product use in unapproved indication 125.18 20.43 183 15574 176435 64306540
Mucormycosis 124.96 20.43 52 15705 7289 64475686
Sepsis 119.62 20.43 207 15550 230134 64252841
Disseminated intravascular coagulation 117.92 20.43 82 15675 32266 64450709
Graft versus host disease 107.59 20.43 57 15700 13756 64469219
Cytomegalovirus infection 103.26 20.43 80 15677 37119 64445856
Trichosporon infection 98.56 20.43 26 15731 866 64482109
Respiratory failure 95.82 20.43 154 15603 161029 64321946
Herpes simplex oesophagitis 94.97 20.43 20 15737 242 64482733
Pyrexia 93.73 20.43 324 15433 558320 63924655
Hepatic function abnormal 93.67 20.43 96 15661 64217 64418758
Cytomegalovirus test positive 92.85 20.43 38 15719 5106 64477869
Fungal infection 91.46 20.43 72 15685 34179 64448796
Fungaemia 89.52 20.43 34 15723 3751 64479224
Pneumonia fungal 87.67 20.43 43 15714 8834 64474141
Acute graft versus host disease in intestine 87.46 20.43 33 15724 3576 64479399
Septic shock 84.58 20.43 116 15641 105321 64377654
Fatigue 84.30 20.43 39 15718 748691 63734284
Candida infection 81.64 20.43 65 15692 31354 64451621
Systemic candida 78.26 20.43 34 15723 5295 64477680
Enterococcal infection 74.84 20.43 45 15712 13821 64469154
Platelet count decreased 69.64 20.43 137 15620 167574 64315401
Cytokine release syndrome 69.40 20.43 50 15707 20779 64462196
Systemic mycosis 66.45 20.43 24 15733 2299 64480676
Dizziness 63.13 20.43 14 15743 430149 64052826
Haemophagocytic lymphohistiocytosis 62.66 20.43 44 15713 17565 64465410
Acute myeloid leukaemia recurrent 62.22 20.43 24 15733 2760 64480215
Venoocclusive liver disease 60.60 20.43 35 15722 9980 64472995
Pathogen resistance 58.27 20.43 37 15720 12506 64470469
Meningoencephalitis herpetic 57.23 20.43 20 15737 1741 64481234
Arthralgia 56.27 20.43 19 15738 442241 64040734
Fall 54.63 20.43 17 15740 416809 64066166
Acute graft versus host disease in liver 54.21 20.43 19 15738 1668 64481307
Drug resistance 54.01 20.43 54 15703 35048 64447927
Enterococcal sepsis 53.96 20.43 21 15736 2473 64480502
Bacterial sepsis 53.10 20.43 29 15728 7428 64475547
Off label use 52.17 20.43 297 15460 632509 63850466
Cystitis haemorrhagic 51.35 20.43 29 15728 7927 64475048
Drug ineffective 50.01 20.43 363 15394 839884 63643091
Chronic graft versus host disease 49.15 20.43 26 15731 6250 64476725
Hypoalbuminaemia 49.00 20.43 38 15719 17636 64465339
Thrombotic microangiopathy 48.78 20.43 37 15720 16618 64466357
Pain 48.03 20.43 39 15718 553472 63929503
Fusarium infection 47.86 20.43 17 15740 1552 64481423
Blood bilirubin increased 47.13 20.43 64 15693 57489 64425486
Headache 46.31 20.43 37 15720 529430 63953545
Gastrointestinal fungal infection 46.19 20.43 12 15745 376 64482599
Engraft failure 45.23 20.43 13 15744 598 64482377
Bacteraemia 44.37 20.43 43 15714 26868 64456107
Disseminated aspergillosis 44.08 20.43 13 15744 655 64482320
Aspartate aminotransferase increased 43.92 20.43 93 15664 119695 64363280
Renal failure 43.92 20.43 120 15637 181568 64301407
Lymphoid tissue hypoplasia 43.39 20.43 12 15745 479 64482496
Staphylococcal sepsis 43.05 20.43 31 15726 12868 64470107
Cholestatic liver injury 42.96 20.43 20 15737 3659 64479316
Weissella infection 42.60 20.43 7 15750 17 64482958
Thymus hypoplasia 42.42 20.43 12 15745 521 64482454
Pneumonia 42.40 20.43 257 15500 559319 63923656
Tumour lysis syndrome 41.70 20.43 36 15721 19404 64463571
Acute respiratory distress syndrome 40.89 20.43 49 15708 38886 64444089
Sinus polyp 39.63 20.43 11 15746 445 64482530
Glomerulosclerosis 39.37 20.43 13 15744 952 64482023
Cerebral aspergillosis 39.28 20.43 15 15742 1678 64481297
Liver abscess 38.89 20.43 21 15736 5259 64477716
Mucosal inflammation 38.76 20.43 61 15696 62523 64420452
Candida sepsis 38.65 20.43 16 15741 2212 64480763
Pleural effusion 38.27 20.43 91 15666 126468 64356507
Malaise 38.12 20.43 25 15732 396222 64086753
Renal impairment 37.55 20.43 94 15663 134923 64348052
Botulism 37.40 20.43 10 15747 351 64482624
Delayed graft function 37.00 20.43 17 15740 3019 64479956
Neutrophil count decreased 36.87 20.43 67 15690 77129 64405846
Mucosal disorder 36.86 20.43 17 15740 3045 64479930
Alanine aminotransferase increased 36.80 20.43 95 15662 138936 64344039
Nasopharyngitis 36.65 20.43 3 15754 196070 64286905
Product dose omission issue 36.35 20.43 3 15754 194744 64288231
Cystitis viral 35.98 20.43 11 15746 627 64482348
Mixed liver injury 35.43 20.43 20 15737 5461 64477514
Pain in extremity 35.21 20.43 15 15742 303070 64179905
Immunosuppressant drug level increased 35.19 20.43 22 15735 7237 64475738
Necrotising oesophagitis 35.13 20.43 11 15746 679 64482296
White blood cell count decreased 34.94 20.43 101 15656 157736 64325239
Nasal abscess 34.71 20.43 8 15749 150 64482825
Dyspnoea 34.59 20.43 78 15679 718596 63764379
Peripheral swelling 34.54 20.43 5 15752 209148 64273827
Rhinocerebral mucormycosis 34.40 20.43 10 15747 479 64482496
Engraftment syndrome 33.72 20.43 12 15745 1101 64481874
Idiopathic pneumonia syndrome 33.25 20.43 10 15747 539 64482436
Asthenia 32.53 20.43 34 15723 428010 64054965
Graft versus host disease in gastrointestinal tract 32.33 20.43 19 15738 5593 64477382
Blast cell count increased 32.10 20.43 12 15745 1267 64481708
Geotrichum infection 32.05 20.43 11 15746 907 64482068
Cytomegalovirus enterocolitis 31.42 20.43 12 15745 1343 64481632
Staphylococcal infection 30.83 20.43 49 15708 50629 64432346
Bacterial infection 30.56 20.43 34 15723 24916 64458059
Graft versus host disease in skin 30.53 20.43 18 15739 5329 64477646
Adenovirus infection 30.25 20.43 20 15737 7235 64475740
Lymphocyte count decreased 29.95 20.43 43 15714 40656 64442319
Graft versus host disease in liver 29.92 20.43 12 15745 1529 64481446
Plasma cell leukaemia 29.83 20.43 12 15745 1541 64481434
Disseminated cryptococcosis 29.73 20.43 12 15745 1555 64481420
Alopecia 29.72 20.43 3 15754 165687 64317288
Acute lymphocytic leukaemia recurrent 29.62 20.43 16 15741 4010 64478965
Biloma 29.49 20.43 7 15750 150 64482825
Klebsiella infection 29.31 20.43 25 15732 13256 64469719
Oesophagitis 29.15 20.43 31 15726 21599 64461376
Liver disorder 28.97 20.43 49 15708 53302 64429673
Nephropathy toxic 28.90 20.43 28 15729 17486 64465489
Epstein-Barr virus infection 28.57 20.43 24 15733 12464 64470511
Enterobacter infection 28.06 20.43 15 15742 3681 64479294
Drug intolerance 27.77 20.43 6 15751 187986 64294989
Weight increased 27.37 20.43 9 15748 213339 64269636
Mucosal erosion 27.29 20.43 12 15745 1922 64481053
Depression 26.77 20.43 6 15751 183285 64299690
Pseudomembranous colitis 26.64 20.43 16 15741 4900 64478075
Toxicity to various agents 26.36 20.43 30 15727 363483 64119492
Acute myeloid leukaemia 26.30 20.43 33 15724 27430 64455545
Drug-induced liver injury 26.18 20.43 44 15713 47599 64435376
Hypokalaemia 26.00 20.43 77 15680 121826 64361149
Rash morbilliform 25.98 20.43 16 15741 5125 64477850
Blood urea increased 25.91 20.43 42 15715 44111 64438864
Neutropenic colitis 25.06 20.43 15 15742 4566 64478409
Device related infection 24.98 20.43 34 15723 30592 64452383
Neutropenia 24.79 20.43 120 15637 239504 64243471
Kidney fibrosis 24.72 20.43 13 15744 3088 64479887
Pruritus 24.64 20.43 24 15733 312376 64170599
Bacterial toxaemia 24.13 20.43 6 15751 157 64482818
Leukaemia recurrent 23.93 20.43 12 15745 2582 64480393
Chest pain 23.90 20.43 14 15743 235966 64247009
Nausea 23.86 20.43 105 15652 785695 63697280
Pseudomonal sepsis 23.38 20.43 15 15742 5157 64477818
Candida test positive 23.11 20.43 9 15748 1061 64481914
Drug ineffective for unapproved indication 23.06 20.43 33 15724 31100 64451875
Aspergillus test positive 22.85 20.43 8 15749 700 64482275
Drug hypersensitivity 22.85 20.43 15 15742 237800 64245175
Reactive gastropathy 22.66 20.43 7 15750 413 64482562
Blood pressure increased 22.63 20.43 7 15750 172545 64310430
Viral haemorrhagic cystitis 22.61 20.43 10 15747 1625 64481350
Gait disturbance 22.55 20.43 7 15750 172148 64310827
Hypersensitivity 22.35 20.43 10 15747 196442 64286533
Oral disorder 22.19 20.43 18 15739 8903 64474072
Oral fungal infection 22.06 20.43 12 15745 3049 64479926
Staphylococcal bacteraemia 21.85 20.43 19 15738 10336 64472639
Overdose 21.79 20.43 6 15751 159560 64323415
Pulmonary mucormycosis 21.78 20.43 8 15749 804 64482171
Gamma-glutamyltransferase increased 21.77 20.43 41 15716 48469 64434506
Pulmonary haemorrhage 21.71 20.43 21 15736 13088 64469887
Blood lactate dehydrogenase increased 21.53 20.43 33 15724 33045 64449930
Myocardial infarction 21.26 20.43 7 15750 165814 64317161
Functional gastrointestinal disorder 21.24 20.43 13 15744 4118 64478857
Hyperbilirubinaemia 21.14 20.43 26 15731 21179 64461796
Hypoxia 21.04 20.43 58 15699 88091 64394884
Cerebral ventricle collapse 20.44 20.43 5 15752 122 64482853

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J02AX05 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIMYCOTICS FOR SYSTEMIC USE
ANTIMYCOTICS FOR SYSTEMIC USE
Other antimycotics for systemic use
FDA CS M0519359 Lipopeptides
FDA EPC N0000175507 Echinocandin Antifungal
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000935 Antifungal Agents
CHEBI has role CHEBI:35441 antiinfective agents

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Candidiasis of the esophagus indication 20639004 DOID:13146
Disseminated candidiasis indication 70572005
Candidal septicemia indication 187022007
Candidemia indication 432261003
Prevention of Disseminated Candidiasis indication
Candida Peritonitis indication
Oropharyngeal Candidiasis off-label use
Intravascular hemolysis contraindication 15601008
Kidney disease contraindication 90708001 DOID:557
Liver function tests abnormal contraindication 166603001




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.09 acidic
pKa2 10.7 acidic
pKa3 12.91 acidic
pKa4 13.44 acidic
pKa5 13.52 acidic
pKa6 13.9 acidic
pKa7 13.91 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
EQ 100MG BASE/VIAL MYCAMINE ASTELLAS N021506 June 27, 2006 RX INJECTABLE INTRAVENOUS Dec. 20, 2022 TREATMENT OF CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONITIS AND ABSCESSES WITHOUT MENINGOENCEPHALITIS AND/OR OCULAR DISSEMINATION IN PEDIATRIC PATIENTS YOUNGER THAN 4 MONTHS OF AGE
EQ 50MG BASE/VIAL MYCAMINE ASTELLAS N021506 March 16, 2005 RX INJECTABLE INTRAVENOUS Dec. 20, 2022 TREATMENT OF CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONITIS AND ABSCESSES WITHOUT MENINGOENCEPHALITIS AND/OR OCULAR DISSEMINATION IN PEDIATRIC PATIENTS YOUNGER THAN 4 MONTHS OF AGE
EQ 100MG BASE/VIAL MYCAMINE ASTELLAS N021506 June 27, 2006 RX INJECTABLE INTRAVENOUS June 20, 2023 PEDIATRIC EXCLUSIVITY
EQ 50MG BASE/VIAL MYCAMINE ASTELLAS N021506 March 16, 2005 RX INJECTABLE INTRAVENOUS June 20, 2023 PEDIATRIC EXCLUSIVITY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Beta-1,3-glucan synthase catalytic subunit 1 Enzyme INHIBITOR CHEMBL CHEMBL
Beta-1,3-glucan synthase Unclassified WOMBAT-PK

External reference:

IDSource
D02465 KEGG_DRUG
208538-73-2 SECONDARY_CAS_RN
4024920 VANDF
4024948 VANDF
C1120386 UMLSCUI
CHEBI:600520 CHEBI
CHEMBL457547 ChEMBL_ID
CHEMBL1237070 ChEMBL_ID
D000077551 MESH_DESCRIPTOR_UI
DB01141 DRUGBANK_ID
8069 INN_ID
R10H71BSWG UNII
477468 PUBCHEM_CID
325887 RXNORM
19567 MMSL
334346 MMSL
66902 MMSL
d05487 MMSL
010714 NDDF
010715 NDDF
416127003 SNOMEDCT_US
416233001 SNOMEDCT_US
426226002 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Micafungin HUMAN PRESCRIPTION DRUG LABEL 1 0143-9361 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 10 mg INTRAVENOUS ANDA 27 sections
Micafungin HUMAN PRESCRIPTION DRUG LABEL 1 0143-9362 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 mg INTRAVENOUS ANDA 27 sections
Mycamine HUMAN PRESCRIPTION DRUG LABEL 1 0469-3211 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 mg INTRAVENOUS NDA 27 sections
Mycamine HUMAN PRESCRIPTION DRUG LABEL 1 0469-3211 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 mg INTRAVENOUS NDA 27 sections
Mycamine HUMAN PRESCRIPTION DRUG LABEL 1 0469-3211 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 mg INTRAVENOUS NDA 27 sections
Mycamine HUMAN PRESCRIPTION DRUG LABEL 1 0469-3250 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 10 mg INTRAVENOUS NDA 27 sections
Mycamine HUMAN PRESCRIPTION DRUG LABEL 1 0469-3250 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 10 mg INTRAVENOUS NDA 27 sections
Mycamine HUMAN PRESCRIPTION DRUG LABEL 1 0469-3250 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 10 mg INTRAVENOUS NDA 27 sections
Micafungin HUMAN PRESCRIPTION DRUG LABEL 1 25021-190 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 mg INTRAVENOUS ANDA 29 sections
Micafungin HUMAN PRESCRIPTION DRUG LABEL 1 25021-191 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 100 mg INTRAVENOUS ANDA 29 sections
Micafungin HUMAN PRESCRIPTION DRUG LABEL 1 42023-229 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 10 mg INTRAVENOUS NDA 26 sections
Micafungin HUMAN PRESCRIPTION DRUG LABEL 1 42023-230 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 mg INTRAVENOUS NDA 26 sections
Micafungin HUMAN PRESCRIPTION DRUG LABEL 1 60505-6119 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 10 mg INTRAVENOUS ANDA 27 sections
Micafungin HUMAN PRESCRIPTION DRUG LABEL 1 60505-6120 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 mg INTRAVENOUS ANDA 27 sections
Micafungin HUMAN PRESCRIPTION DRUG LABEL 1 63323-728 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 mg INTRAVENOUS ANDA 30 sections
Micafungin HUMAN PRESCRIPTION DRUG LABEL 1 63323-729 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 100 mg INTRAVENOUS ANDA 30 sections
Micafungin HUMAN PRESCRIPTION DRUG LABEL 1 63323-729 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 100 mg INTRAVENOUS ANDA 30 sections
Micafungin HUMAN PRESCRIPTION DRUG LABEL 1 70594-036 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 10 mg INTRAVENOUS ANDA 34 sections
Micafungin HUMAN PRESCRIPTION DRUG LABEL 1 70594-037 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 mg INTRAVENOUS ANDA 34 sections